Cargando…

Functional genomics screen identifies YAP1 as a key determinant to enhance treatment sensitivity in lung cancer cells

Survival for lung cancer patients remains dismal and is largely attributed to treatment resistance. To identify novel target genes the modulation of which could modify platinum resistance, we performed a high-throughput RNAi screen and identified Yes-associated protein (YAP1), a transcription coacti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Haiying, Zhang, Zhenfeng, Rodriguez-Barrueco, Ruth, Borczuk, Alain, Liu, Huijie, Yu, Jiyang, Silva, Jose M., Cheng, Simon K., Perez-Soler, Roman, Halmos, Balazs
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045371/ https://www.ncbi.nlm.nih.gov/pubmed/26716514 http://dx.doi.org/10.18632/oncotarget.6721

Ejemplares similares

PHLDA2 is a key oncogene-induced negative feedback inhibitor of EGFR/ErbB2 signaling via interference with AKT signaling
por: Wang, Xiaoqi, et al.
Publicado: (2015)

Smurf2 inhibition enhances chemotherapy and radiation sensitivity in non-small-cell lung cancer
por: Chaudhary, Kunal R., et al.
Publicado: (2022)

Heterogeneous Expression of PD-L1, B7x, B7-H3, and HHLA2 in Pulmonary Sarcomatoid Carcinoma and the Related Regulatory Signaling Pathways
por: Wang, Feng, et al.
Publicado: (2023)

Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical Practice
por: Singh, Aditi P., et al.
Publicado: (2020)

Is pembrolizumab monotherapy the optimal treatment for elderly patients with PD-L1 positive advanced non-small cell lung cancer?
por: Mienko, Fiona, et al.
Publicado: (2020)

A comprehensive enhancer screen identifies TRAM2 as a key and novel mediator of YAP oncogenesis
por: Li, Li, et al.
Publicado: (2021)

Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literature
por: Deng, Lei, et al.
Publicado: (2018)

Blockade of AXL activation overcomes acquired resistance to EGFR tyrosine kinase inhibition in non-small cell lung cancer
por: Wang, Feng, et al.
Publicado: (2019)

Exploring causes and consequences of early discontinuation of durvalumab after chemoradiotherapy for non-small cell lung cancer
por: Pennock, Michael, et al.
Publicado: (2023)

Transcriptional and epigenomic profiling identifies YAP signaling as a key regulator of intestinal epithelium maturation
por: Pikkupeura, Laura M., et al.
Publicado: (2023)

MYC is a critical target of FBXW7
por: Sato, Mai, et al.
Publicado: (2014)

A covalent inhibitor of the YAP–TEAD transcriptional complex identified by high-throughput screening
por: Nutsch, Kayla, et al.
Publicado: (2023)

EGFR-mutated lung cancer: a paradigm of molecular oncology
por: Zhang, Zhenfeng, et al.
Publicado: (2010)

In Vivo RNAi Screening Identifies Regulators of Actin Dynamics as Key Determinants of Lymphoma Progression
por: Meacham, Corbin E., et al.
Publicado: (2009)

YAP Inactivation by Soft Mechanotransduction Relieves MAFG for Tumor Cell Dedifferentiation
por: Lv, Jiadi, et al.
Publicado: (2023)

AXL kinase as a novel target for cancer therapy
por: Wu, Xiaoliang, et al.
Publicado: (2014)

Nuclear YAP localization as a key regulator of podocyte function
por: Bonse, Jakob, et al.
Publicado: (2018)

Nanochannel Array on Electrochemically Polarized Screen Printed Carbon Electrode for Rapid and Sensitive Electrochemical Determination of Clozapine in Human Whole Blood
por: Wang, Kai, et al.
Publicado: (2022)

Endogenous glutamate determines ferroptosis sensitivity via ADCY10-dependent YAP suppression in lung adenocarcinoma
por: Zhang, Xiao, et al.
Publicado: (2021)

Therapeutic Interception of Early Lung Adenocarcinoma Progression: Not Just How, but When?
por: Borczuk, Alain C.
Publicado: (2021)

Prognostic considerations of the new World Health Organization classification of lung adenocarcinoma
por: Borczuk, Alain C.
Publicado: (2016)

YAP as a key regulator of adipo-osteogenic differentiation in human MSCs
por: Lorthongpanich, Chanchao, et al.
Publicado: (2019)

Myofibroblast YAP/TAZ activation is a key step in organ fibrogenesis
por: He, Xiaolin, et al.
Publicado: (2022)

Thyroid Dysfunction in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors (ICIs): Outcomes in a Multiethnic Urban Cohort
por: D’Aiello, Angelica, et al.
Publicado: (2021)

Determination of the Absolute Light Yields of LuYAP and LYSO
por: Kronberger, Matthias, et al.
Publicado: (2009)

The role of YAP/TAZ activity in cancer metabolic reprogramming
por: Zhang, Xiaodong, et al.
Publicado: (2018)

The biology of YAP in programmed cell death
por: Cheng, Yifan, et al.
Publicado: (2022)

NEK1-Mediated Phosphorylation of YAP1 Is Key to Prostate Cancer Progression
por: Ghosh, Ishita, et al.
Publicado: (2023)

SUFU suppresses ferroptosis sensitivity in breast cancer cells via Hippo/YAP pathway
por: Fang, Kun, et al.
Publicado: (2022)

WW Domain-Containing Proteins YAP and TAZ in the Hippo Pathway as Key Regulators in Stemness Maintenance, Tissue Homeostasis, and Tumorigenesis
por: Chen, Yu-An, et al.
Publicado: (2019)

Haploid Mammalian Genetic Screen Identifies UBXD8 as a Key Determinant of HMGCR Degradation and Cholesterol Biosynthesis
por: Loregger, Anke, et al.
Publicado: (2017)

OTUB1 suppresses Hippo signaling via modulating YAP protein in gastric cancer
por: Yan, Cheng, et al.
Publicado: (2022)

Genome-wide CRISPR screen identified Rad18 as a determinant of doxorubicin sensitivity in osteosarcoma
por: Du, Mingrui, et al.
Publicado: (2022)

YAP determines the cell fate of injured mouse hepatocytes in vivo
por: Miyamura, Norio, et al.
Publicado: (2017)

The β-catenin/YAP signaling axis is a key regulator of melanoma-associated fibroblasts
por: Liu, Tianyi, et al.
Publicado: (2019)

Targeting YAP in malignant pleural mesothelioma
por: Zhang, Wen‐Qian, et al.
Publicado: (2017)

ZNF213 negatively controls triple negative breast cancer progression via Hippo/YAP signaling
por: Liu, Yun, et al.
Publicado: (2021)

Modulation of ErbB2 Blockade in ErbB2-Positive Cancers: The Role of ErbB2 Mutations and PHLDA1
por: Li, Guangyuan, et al.
Publicado: (2014)

A genome-wide screen identifies YAP/WBP2 interplay conferring growth advantage on human epidermal stem cells
por: Walko, Gernot, et al.
Publicado: (2017)

YAP/TAZ: Key Players for Rheumatoid Arthritis Severity by Driving Fibroblast Like Synoviocytes Phenotype and Fibro-Inflammatory Response
por: Caire, Robin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rvrvu4spmotn9kesepr1kov4sl